januari
world
health
organ
declar
identif
chines
health
author
novel
coronaviru
classifi
new
viru
initi
emerg
chines
citi
wuhan
decemb
led
sharpli
spread
outbreak
human
respiratori
diseas
within
peopl
republ
china
sever
countri
worldwid
march
declar
global
pandem
current
itali
second
affect
countri
infect
china
first
autochthon
infect
case
confirm
itali
februari
march
case
death
regist
itali
consid
recent
evolut
italian
epidemiolog
pictur
mani
healthcar
facil
like
charg
manag
patient
affect
next
day
l
spallanzani
nation
institut
infecti
diseas
ircc
first
italian
hospit
admit
patient
affect
therefor
use
share
protocol
clinic
manag
confirm
case
appli
within
institut
order
support
facil
may
limit
experi
treat
patient
procedur
describ
present
document
appli
agreement
region
network
infecti
diseas
region
hospit
medic
specialti
network
activ
cooper
region
agenc
health
emerg
are
latter
charg
respons
territori
health
emerg
transport
patient
within
hospit
network
recommend
describ
within
document
base
limit
clinic
evid
consequ
consid
expert
opinion
may
modifi
accord
newli
produc
literatur
data
suspect
case
person
acut
respiratori
infect
defin
acut
onset
least
one
follow
signsymptom
fever
cough
respiratori
difficulti
breath
without
anoth
etiolog
complet
explain
clinic
present
histori
travelsstay
countri
document
local
transmiss
within
day
preced
symptom
onset
b
person
acut
respiratori
infect
histori
close
contact
probabl
confirm
case
within
day
preced
symptom
onset
c
person
sever
respiratori
infect
fever
least
one
signsymptom
respiratori
diseas
eg
cough
difficulti
breath
requir
hospit
admiss
anoth
etiolog
complet
explain
clinic
present
set
primari
carea
depart
countriesarea
autochthon
transmiss
observ
patient
singssymptom
acut
respiratori
infect
consid
suspect
case
accord
report
avail
http
suspect
case
result
real
time
pcr
perform
region
refer
laboratori
doubt
conclus
result
pancoronaviru
test
posit
person
laboratori
confirm
infect
perform
nation
refer
laboratori
istituto
superior
di
irrespect
clinic
sign
symptom
case
present
clinic
featur
suggest
complic
cours
infect
individu
present
clinic
symptom
sign
consid
burden
clinic
symptom
higher
risk
complic
goal
clinic
manag
addit
one
state
asymptomat
patient
closer
monitor
clinic
condit
analyt
data
strategi
aim
acceler
viral
clearanc
use
potenti
efficaci
experiment
antivir
drug
characterist
prostrat
sever
asthenia
high
fever
andor
persist
cough
clinic
radiolog
sign
lung
involv
clinic
laboratorist
paramet
clinic
sever
andor
respiratori
impair
addit
microbiolog
diagnost
influenza
viru
detect
andor
respiratori
agent
multiplex
pcr
singl
rhinopharyng
swab
sampl
serolog
avail
urinari
l
pneumophila
pneumonia
antigen
detect
case
avail
sampl
repres
lower
respiratori
tract
eg
sputum
perform
gram
stain
cultur
avoid
aerosolgener
procedur
induc
sputum
higher
infecti
risk
healthcar
worker
case
fever
perform
least
blood
cultur
possibl
start
new
antimicrobi
therapi
clinic
monitor
period
clinic
reevalu
oncework
shift
thriceday
period
vital
sign
record
blood
pressur
heart
rate
respiratori
rate
gc
bodi
temperatur
oncework
shift
thriceday
order
earli
identifi
possibl
rapid
worsen
respiratori
function
requir
increas
level
care
arteri
blood
ga
analysi
monitor
mainli
th
th
day
clinic
worsen
evalu
togeth
intens
care
specialist
charg
virolog
monitor
rtpcr
perform
rhinopharyng
swab
everi
hour
persist
neg
imag
diagnost
chest
xray
use
firstlin
radiolog
examin
followup
rapid
assess
certain
pulmonarythorac
emerg
quick
easi
perform
case
necess
perform
use
portabl
system
chest
comput
tomographi
without
contrast
high
sensit
identifi
quantifi
lung
parenchym
involv
absolut
indic
stage
diseas
highli
valuabl
togeth
blood
ga
analysi
predict
clinic
worsen
chest
ct
report
evalu
togeth
intens
care
specialist
charg
antivir
therapi
lopinavirritonavir
mg
tablet
tablet
day
hydroxychloroquin
phosphat
mg
tablet
tablet
load
dose
follow
mg
tablet
tablet
day
chloroquin
phosphat
mg
tablet
tablet
day
altern
lopinavirritonavir
darunavir
mg
tablet
tablet
plu
ritonavir
mg
tablet
tablet
day
chloroquin
hydrossichloroquin
administr
defici
test
perform
support
therapi
symptomat
oral
rehydr
consid
antimicrobi
therapi
broad
spectrumempir
base
microbiolog
result
prompt
avail
case
necess
patient
affect
respiratori
symptom
clinic
unstabl
critic
condit
eg
mew
clinic
deterior
score
patient
present
sever
respiratori
condit
relat
infect
andor
complic
adjunct
goal
clinic
manag
stage
strict
monitor
especi
th
th
day
sinc
symptom
onset
order
ensur
immedi
life
support
increas
level
care
whenev
requir
mainten
adequ
peripher
oxygen
administr
use
potenti
efficaci
antivir
experiment
drug
aim
rapidli
reduc
viral
replic
empir
target
treatment
possibl
bacteri
coinfect
prompt
assess
need
drug
aim
modul
immun
inflammatori
respons
order
counteract
evolut
ard
characterist
clinic
andor
laboratorist
evid
worsen
ga
exchang
mildtomoder
dyspnoea
high
respiratori
rate
short
breath
low
peripher
alter
arteri
blood
gase
breath
room
air
without
critic
warn
sign
sever
respiratori
failur
respiratori
distress
conscious
disord
hypotens
shock
addit
microbiolog
diagnost
influenza
viru
detect
andor
respiratori
agent
multiplex
pcr
singl
rhinopharyng
swab
sampl
serolog
avail
urinari
l
pneumophila
pneumonia
antigen
detect
case
avail
sampl
repres
lower
respiratori
tract
eg
sputum
perform
gram
stain
cultur
avoid
aerosolgener
procedur
induc
sputum
higher
infecti
risk
healthcar
worker
case
fever
perform
least
blood
cultur
possibl
start
new
antimicrobi
therapi
eventu
diagnost
base
specif
clinic
pictur
eg
hiv
test
p
jirovecii
detect
respiratori
fluid
mrsa
nasal
swab
clinic
monitor
strict
clinic
reevalu
strict
period
vital
sign
record
blood
pressur
heart
rate
respiratori
rate
gc
bodi
temperatur
order
earli
identifi
possibl
rapid
worsen
respiratori
function
requir
increas
level
care
arteri
blood
ga
analysi
monitor
mainli
th
th
day
evalu
togeth
intens
care
specialist
charg
consult
intens
care
specialist
virolog
immunolog
biochem
monitor
rtpcr
perform
rhinopharyng
swab
everi
hour
persist
neg
plasma
level
ddimer
ferritin
fibrinogen
creactiv
protein
tryglicerid
lactat
dehydrogenas
ldh
imag
diagnost
chest
xray
use
firstlin
radiolog
examin
followup
rapid
assess
certain
pulmonarythorac
emerg
quick
easi
perform
case
necess
perform
use
portabl
system
chest
comput
tomographi
without
contrast
high
sensit
identifi
quantifi
lung
parenchym
involv
perform
everi
patient
affect
lung
involv
caus
respiratori
failur
use
contrast
case
specif
clinic
question
eg
pulmonari
embol
chest
ct
report
evalu
togeth
intens
care
specialist
charg
ecocardiographi
indic
case
suspect
hearth
failur
contribut
factor
lung
involvementrespiratori
failur
current
medic
vaccin
proven
effect
either
old
new
agent
propos
explor
treatment
clinic
trial
still
underway
avail
data
base
anecdot
experi
expert
opinion
chloroquin
old
wide
use
antimalari
drug
also
efficaci
antiinflammatori
agent
rheumatolog
diseas
earlier
studi
demonstr
potenti
antivir
effect
drug
sar
avian
influenza
postul
antivir
action
chloroquin
may
depend
sever
mechan
chang
cell
membran
ph
necessari
viral
fusion
interfer
glycosyl
viral
protein
hydroxychloroquin
analogu
chloroquin
prove
similar
better
invitro
efficaci
recent
studi
demonstr
invitro
efficaci
chloroquin
remdesivir
inhibit
replic
moreov
emerg
report
china
suggest
chloroquin
shown
superior
reduc
sever
durat
clinic
diseas
without
signific
advers
event
almost
one
hundr
patient
light
result
expert
consensu
group
china
recommend
chloroquin
treatment
recommend
dosag
infect
chloroquin
mg
bid
hydroxychloroquin
mg
bid
day
combin
anoth
antivir
agent
lopinavirritonavir
remdesivir
seriou
advers
effect
may
includ
qt
prolong
torsad
de
point
reduct
seizur
threshold
anaphylaxi
anaphylactoid
reaction
neuromuscular
impair
neuropsychiatr
disord
potenti
increas
delirium
pancytopenia
neutropenia
thrombocytopenia
aplast
anemia
hepat
common
advers
reaction
nausea
vomit
diarrhea
abdomin
pain
visual
disturb
headach
extrapyramid
symptom
import
check
start
treatment
treatment
monitor
complet
blood
count
qt
interv
contraind
porphyria
defici
epilepsi
heart
failur
recent
myocardi
infarct
lopinavirritonavir
wellknown
proteas
inhibitor
wide
use
mani
year
treatment
hiv
infect
compar
remdesivir
lopinavirritonavir
advantag
wide
avail
establish
toxic
drugdrug
interact
profil
antivir
action
coronaviru
infect
previous
demonstr
invitro
invivo
anim
human
data
studi
conduct
sar
lopinavir
act
antivir
activ
inhibit
viral
replic
hiv
infect
ritonavir
act
boost
lopinavir
plasma
level
although
limit
anecdot
data
avail
clinic
efficaci
lopinavirritonavir
infect
far
seem
rapidli
reduc
replic
lopinavirritonavir
current
investig
within
sever
rct
china
recommend
dose
mg
bid
standard
dose
use
hiv
therapi
case
swallow
difficulti
unconsci
patient
oral
solut
lopinavirritonavir
administr
tablet
crush
seriou
advers
effect
may
includ
hypersensit
reaction
angioedema
stevensjohnson
syndrom
toxic
epiderm
necrolysi
ekg
alter
qt
prolong
torsad
de
point
av
block
pr
prolong
pancytopenia
pancreat
hepatotox
common
advers
reaction
gastrointestin
symptom
nauseavomit
diarrhea
monitor
transaminas
level
treatment
drugdrug
interact
treatment
start
light
possibl
shortag
lopinavirritonavir
stock
due
increas
prescript
suggest
possibl
use
darunavirritonavir
dosag
mg
ever
hour
replac
lopinavirritonavir
consid
similar
mechan
action
optim
safeti
profil
remdesivir
novel
nucleotid
analogu
current
evalu
clinic
trial
ebola
infect
remdesevir
shown
clinic
excel
activ
coronaviru
infect
sar
mer
invitro
anim
model
act
inhibit
viral
polymeras
recent
studi
explor
invitro
activ
remdesivir
chloroquin
demonstr
efficaci
drug
inhibit
replic
recent
case
report
describ
use
remdesivir
request
compassion
use
first
patient
unit
state
two
ongo
clinic
random
clinic
trial
china
evalu
remdesivir
moder
sever
infect
check
drugdrug
interact
antivir
therapi
pleas
visit
univers
liverpool
websit
http
tocilizumab
tcz
antihuman
receptor
monoclon
antibodi
inhibit
signal
transduct
bind
main
approv
indic
rheumatoid
arthriti
associ
methotrex
us
food
drug
administr
approv
tcz
treatment
cytokin
releas
syndrom
cr
consist
system
inflammatori
respons
caus
massiv
releas
proinflammatori
cytokin
respons
iatrogen
eg
cart
therapi
infect
stimuli
although
lack
data
pathogenesi
studi
china
show
possibl
correl
massiv
inflamm
sever
lung
damag
rapid
evolut
fatal
pneumonia
inde
patient
signific
differ
plasmat
level
observ
differ
stage
diseas
higher
express
sever
case
mild
one
moreov
biopsi
sampl
autopsi
sever
patient
histolog
examin
show
diffus
alveolar
damag
cellular
fibromyxoid
exud
interstiti
mononuclear
inflammatori
infiltr
suggest
sever
immun
injuri
despit
lack
clinic
trial
tcz
efficaci
safeti
treatment
china
tcz
recent
approv
patient
affect
sever
pulmonari
complic
nation
health
commiss
peopl
republ
china
preliminari
data
observ
studi
conduct
china
sever
case
receiv
tcz
show
improv
clinic
radiolog
outcom
tcz
potenti
treatment
strategi
sever
critic
patient
particular
patient
could
benefit
tcz
therapi
patient
respiratori
symptom
unstabl
sever
critic
condit
eg
clinic
instabl
score
mew
evid
worsen
ga
exchang
mild
moder
dyspnoea
tachypnea
worsen
arteri
blood
ga
analysi
paramet
ambient
air
ambient
air
mmhg
absenc
critic
manifest
sign
alarm
sever
respiratori
failur
respiratori
distress
alter
state
conscious
hypotens
cardiovascular
shock
patient
respiratori
symptom
critic
condit
eg
clinic
instabl
score
mew
evid
ard
moder
ard
accord
berlin
definit
mmhg
mmhg
sever
respiratori
failur
evid
rapid
worsen
respiratori
distress
need
mechan
ventil
presenc
shock
presenc
concomit
organ
failur
need
intens
care
monitor
although
optim
dose
schedul
tcz
treatment
cr
known
intend
posolog
mgkg
intraven
maximum
mgdose
infus
hour
addit
administr
evalu
basi
patient
respons
tcz
hour
apart
case
absencepoor
clinic
improv
clinic
worsen
andor
failur
reduct
baselin
creactiv
protein
reliabl
surrog
marker
failur
normal
andor
failur
reduct
ddimer
fibrinogen
ferritin
level
dosag
adjust
requir
relat
blood
paramet
liver
function
blood
count
accord
indic
specifi
patient
packag
insert
advis
monitor
follow
blood
paramet
full
blood
count
includ
platelet
count
altast
ldh
fibrinogen
ddimer
ferritin
creactiv
protein
differ
time
point
immedi
st
infus
immedi
nd
infus
nd
infus
nd
infus
sever
lifethreaten
infect
alter
blood
paramet
alt
ast
uln
absolut
neutrophil
count
cellmmc
platelet
count
cellmmc
contraind
tcz
treatment
caution
requir
special
categori
pregnancybreastfeed
activ
latent
pulmonari
tuberculosi
bacterialfung
infect
immunerel
rheumat
diseas
concomit
therapi
antireject
drug
immunomodul
therapi
hepatopati
includ
viral
hepat
safeti
profil
tcz
well
known
tqt
studi
common
mark
laboratori
abnorm
low
neutrophil
count
decreas
observ
mean
neutrophil
count
follow
singl
dose
tcz
first
day
posttreat
reach
maximum
approxim
hour
infus
observ
incid
mark
decreas
neutrophil
count
increas
higher
dose
tcz
thrombocytopenia
increas
liver
function
test
also
describ
detail
inform
reader
refer
patient
packag
insert
